A comparison between fluconazole tablets and clotrimazole troches for the treatment of thrush in HIV infection

Spencer W. Redding, George C. Farinacci, Jean A. Smith, Annette W. Fothergill, Michael G. Rinaldi

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Fluconazole, a newly available triazole, has been evaluated extensively as a treatment for thrush. It has been effective in the treatment of this condition in patients with HIV infection. Clotrimazole troches have been a common treatment for thrush in patients with HIV infection for several years. This study compared the efficacy and safety of fluconazole 100 mg tablets once per day versus clotrimazole 10 mg troches five times per day in the treatment of thrush in patients with HIV infection. Patients were evaluated at baseline, day 7, 14, 28, and 42. The following parameters were evaluated: clinical cure, colonization at the end of treatment, relapse at day 28, and relapse at day 42. Side effects including liver enzyme values were also monitored. Clinical cure was superior with fluconazole tablets than with clotrimazole troches. Also, rates of colonization at the end of therapy and relapse at days 28 and 42 were less with fluconazole tablets than with clotrimazole troches. However, these differences were not statistically significant. Patient compliance with fluconazole was superior to that of clotrimazole. This difference was statistically significant. Both fluconazole tablets and clotrimazole troches are effective in treating thrush in patients with HIV infection. The avoidance of multiple‐per‐day dosing would appear to favor fluconazole.

Original languageEnglish (US)
Pages (from-to)24-27
Number of pages4
JournalSpecial Care in Dentistry
Volume12
Issue number1
DOIs
Publication statusPublished - Jan 1992

    Fingerprint

ASJC Scopus subject areas

  • Dentistry(all)

Cite this